*Pemphigus Vulgaris DOI: http://dx.doi.org/10.5772/intechopen.104814*

[33] Zhang W, Wei S, Peng X, Xie S, Zhang Z, Zeng K, et al. Shortterm intravenous infusion of cyclophosphamide in the treatment of refractory Pemphigus Vulgaris: A Retrospective Study. Dermatology. 2021;**237**(2):185-190

[34] Sinha AA, Hoffman MB, Janicke EC. Pemphigus vulgaris: Approach to treatment. European Journal of Dermatology. 2015;**25**:103-113

[35] Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, doubleblind, placebo-controlled, clinical trial of dapsone as a glucocorticoid sparing agent in maintenance-phase pemphigus vulgaris. Archives of Dermatology. 2008;**144**:25-32

[36] Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and future therapeutic strategies. Frontiers in Immunology. 2019;**10**:1418

[37] Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. The British Journal of Dermatology. 2017;**177**:1170-1201

[38] Langrish CL, Bradshaw JM, Francesco MR, Owens TD, Xing Y, Shu J, et al. Preclinical efficacy and antiinflammatory mechanisms of action of the bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. Journal of Immunology. 2021;**206**(7):1454-1468

[39] Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for

pemphigus vulgaris: The phase II BELIEVE study. The British Journal of Dermatology. 2021;**185**(4):745-755

[40] Egu DT, Sigmund AM, Schmidt E, Spindler V, Walter E, Waschke J. A new ex vivo human oral mucosa model reveals that p38MAPK inhibition is not effective to prevent autoantibody-induced mucosal blistering in pemphigus. The British Journal of Dermatology. 2020;**182**:987-994

[41] Murrell DF, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology. 2018;**2**:21

[42] Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clinics in Dermatology. 2011;**29**(4):432-436

[43] De D, Kanwar AJ. Childhood pemphigus. Indian Journal of Dermatology. 2006;**51**:89-95

[44] Kincaid L, Weinstein M. Rituximab therapy for childhood pemphigus vulgaris. Pediatric Dermatology. 2016;**33**(2):e61-e64

[45] Gürcan H, Mabrouk D, Razzaque AA. Management of pemphigus in pediatric patients. Minerva Pediatrica. 2011;**63**(4):279-291

[46] Wananukul S, Pongprasit P. Childhood pemphigus. International Journal of Dermatology. 1999;**38**:29-35

[47] Kaufman AJ, Ahmed AR, Kaplan RP. Pemphigus, myasthenia gravis, and pregnancy. Journal of the American Academy of Dermatology. 1988;**19** (2 Pt 2):414-418

[48] Rangel J. Pregnancy-Associated "Cutaneous Type". Pemphigus Vulgaris Journal. 2016;**20**(1):e101

[49] Kalayciyan A, Engin B, Serdaroglu S, Mat C, Aydemir EH, Kotogyan A. A retrospective analysis of patients with pemphigus vulgaris associated with pregnancy. The British Journal of Dermatology. 2002;**147**(2):396-397

[50] Weinberg ED. Pregnancy-associated depression of cell-mediated immunity. Reviews of Infectious Diseases. 1984;**6**(6):814-831

[51] Gushi M, Yamamoto Y, Mine Y, Awazawa R, Nonaka K, Taira K, et al. Neonatal Pemphigus vulgaris. The Journal of Dermatology. 2008;**35**:529-535

[52] Lin L, Zeng X, Chen Q. Pemphigus and pregnancy. Analysis and summary of case reports over 49 years. Saudi Medical Journal. 2015;**36**(9):1033-1038

[53] Kanwar AJ, Thami GP. Pemphigus vulgaris and pregnancy—A reappraisal. The Australian & New Zealand Journal of Obstetrics & Gynaecology. 1999;**39**:372-373

[54] Braunstein I, Werth V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatologic Therapy. 2013;**26**(4):354-363

[55] Hup JM, Bruinsma RA, Boersma ER, de Jong MC. Neonatal Pemphigus vulgaris: Transplacental transmission of antibodies. Pediatric Dermatology. 1986;**3**:468-472

[56] Daneshpazhooh M, Chams-Davatchi C, Valikhani M, Aghabagheri A, Mortazavizadeh SM, Barzegari M, et al. Pemphigus and pregnancy: A 23-year experience. Indian Journal

of Dermatology, Venereology and Leprology. 2011;**77**:534

[57] Lehman JS, Mueller KK, Schraith DF. Do safe and effective treatment options exist for patients with active Pemphigus vulgaris who plan conception and pregnancy? Archives of Dermatology. 2008;**144**:783-785

[58] Cozzani E, Cacciapuoti M, Parodi A, Rebora A. Pemphigus following tetanus and diphtheria vaccination. The British Journal of Dermatology. 2002;**147**:188-189

[59] De Simone C, Caldarola G, D'agostino M, Zampetti A, Amerio P, Feliciani C. Exacerbation of pemphigus after influenza vaccination. Clinical and Experimental Dermatology. 2008;**33**(6):718-720

[60] Damiani G, Pacifico A, Pelloni F, Iorizzo M. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: Is the second dose therefore contraindicated? Journal of the European Academy of Dermatology and Venereology. 2021;**35**:645-647

[61] Waldman RA, Creed M, Sharp K, et al. Letter in Reply: Toward a COVID-19 vaccine strategy for pemphigus patients on rituximab. Journal of the American Academy of Dermatology. 2020;**84**:197-E198
